Robert J. Kreitman, MD, of the National Cancer Institute, discusses findings on moxetumomab pasudotox in heavily pretreated patients with relapsed or refractory hairy cell leukemia (Abstract 7004).
Sumanta K. Pal, MD, of the City of Hope, and Neeraj Agarwal, MD, of the Huntsman Cancer Institute, University of Utah, discuss the ongoing phase III Talapro-2 study of talazoparib with background enzalutamide in metastatic castration-resistant prostate cancer with DNA damage–repair deficiencies (Abstract TPS5091).
Geertjan Van Tienhoven, MD, PhD, of the Dutch Pancreatic Cancer Group, discusses phase III study findings on preoperative chemoradiotherapy vs immediate surgery for resectable and borderline resectable pancreatic cancer (Abstract LBA4002).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss their perspectives on the top abstracts in bladder cancer presented at the 2018 ASCO Annual Meeting (Abstracts 4507, 4506, 4503, 4504).
Sumanta K. Pal, MD, of City of Hope, and A. Oliver Sartor, MD, of Tulane University School of Medicine, discuss the implications of findings on black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).
Apostolia-Maria Tsimberidou, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses findings on clinical outcomes, including long-term survival, according to the pathway targeted and treatment period (Abstract LBA2553).
